Polynucleotides Efficacy in the Genitourinary Syndrome of Menopause

• Status: Recruiting
• Trial end date: 2022-12-23
• Target enrollment: 0
• Participant gender: Female

Summary

The aim of this study is to determine the efficiency of local polynucleotides-based therapy in the treatment of the genitourinary syndrome of menopause, in postmenopausal Mexican women, and to compare it with gold standard therapy with local conjugated estrogens.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Hospital Regional 1o de Octubre
• Collaborators: Hospital General Regional No. 1 IMSS; Institut d'Investigacions Biomèdiques August Pi i Sunyer; National Polytechnic Institute, Mexico; Universidad Nacional Autonoma de Mexico
• Treatments: Estrogens; Estrogens, Conjugated (USP)

Criteria

Inclusion Criteria:

• Diagnosis of Genitourinary Syndrome of Menopause that presents an MRS > 5 in the urogenital domain, with alterations in the vaginal maturity index (VMI) and in the vaginal pH

Exclusion Criteria:

• Incomplete clinical records or clinical records.

• Age over 70 years.

• Diagnosis of secondary (hereditary) osteoporosis.

• History of prolonged use of steroids.

• Lack of adherence to medical treatment.

• Diagnosis of cancer.

• Diagnosis of depression.

• Diagnosis of Celiac disease or with the presence of alterations in intestinal absorption.

• Allergies to any of the medications administered.